Eng

Flixotide

Quick links to important sections

Flixotide

Selected form

Fluticasone Propionate

Method of action: Antiallergic, Anti-Inflammatory, Antipruritic, Bronchodilator, Corticosteroids, Dermatological Preparations, Decongestant, Decongestant Local, Drugs For Obstructive Airway Diseases, Glucocorticoid, Nasal Preparations

Treatment option: Asthma, Chronic Obstructive Lung Disease

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flixotide

Quick Facts

Property	Description
Active Ingredient	Fluticasone Propionate
Form	Inhalation powder, Pressurised inhalation suspension, Nebuliser suspension, Nasal spray
Pharmacological Class	Inhaled Corticosteroid (ICS)
Origin	Synthetic fluorinated corticosteroid
General Purpose	Prophylactic anti-inflammatory control

What Type of Medicine is Flixotide (Fluticasone Propionate)?

Flixotide is a prescription-only medicinal product containing the single active ingredient Fluticasone Propionate, which is formally classified as an Inhaled Corticosteroid (ICS). This substance is a potent, synthetic fluorinated corticosteroid, not an anabolic steroid, designed specifically to reduce inflammation in the respiratory system. Its primary role is that of a prophylactic treatment, working to stabilize underlying conditions characterized by chronic inflammation rather than providing immediate relief for acute symptoms. This ICS class is recognized for its role in achieving long-term anti-inflammatory control, and using this medicine regularly helps control inflammation over time.

As a glucocorticoid compound, Fluticasone Propionate is structurally engineered for high affinity to local receptors, allowing it to exert a powerful anti-inflammatory action directly on the tissue where it is administered. Its classification as an ICS is clinically recognized for minimizing systemic exposure compared to oral corticosteroids, concentrating the therapeutic effect where it is most needed.

Forms, Composition, and Local Delivery System

Fluticasone Propionate is delivered through specialized dosage forms tailored for direct application, offering several distinct delivery methods. These forms include inhalation powder (DPI), pressurised inhalation suspension (pMDI), nebuliser suspension, and in some uses, a nasal spray, facilitating administration via the inhalation or nasal route. The composition utilizes various delivery vehicles, such as powdered carriers like lactose monohydrate or specialized propellants and excipients, all essential for efficiently transporting the active substance to the mucosal surfaces.

This structure allows the medicine to function as a local delivery system, concentrating its potent topical action on the inflamed surface, such as the lining of the airways. By directly modulating the inflammatory pathways at the cellular level, the medicine helps to consistently reduce swelling and irritation. Fluticasone Propionate is characterized by high and specific topical activity, as the drug is designed to work strongly and specifically on the surface it touches.

What side effects are possible with Flixotide?

Possible Side Effects and Safety Information

The safety profile for Fluticasone Propionate (Flixotide) is officially structured by the consequences of its local administration as an inhaled corticosteroid, as documented in regulatory sources like the EMA and FDA. Side effects are classified by frequency and the body system affected.

Common and Local Reactions

The most frequently documented adverse reactions are typically local effects on the mouth and throat, classified as Common (affecting up to 1 in 10 people). These include oral and oropharyngeal candidiasis (thrush, a fungal infection) and dysphonia (hoarseness). Headache is also commonly reported.

Serious and Systemic Safety Patterns

Certain clinically significant events are documented, although they are generally considered Rare or Very Rare (affecting fewer than 1 in 1,000 to 1 in 10,000 people). One such serious reaction is paradoxical bronchospasm, an acute and immediate worsening of breathing that occurs after administration. Severe allergic reactions, including anaphylaxis, are also listed.

The potential for systemic effects is generally associated with prolonged use of high doses. These Very Rare systemic reactions stem from the medicine's corticosteroid nature and may include signs of adrenal suppression or features of Cushing's syndrome, as well as glaucoma or cataract affecting the eyes.

Population-Specific Considerations

Official labeling includes specific safety considerations for patient populations. In paediatric patients (children and adolescents), there is a documented potential for growth retardation with prolonged use, necessitating appropriate monitoring. Furthermore, caution is advised in patients with severe hepatic impairment due to the possibility of increased systemic exposure, which may heighten the risk of systemic adverse effects.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Fluticasone Propionate overdose centers on the physiological risks associated with prolonged use of doses higher than officially recommended, rather than acute toxicity from a single event.

Overdose Scope

Property	Official Regulatory Statement
Documented Overdose Presentations	Symptoms and signs of Hypercorticism (Cushingoid features); Documented Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, indicated by reduced plasma cortisol levels.
Dose-related or Exposure-related Factors	Overdosage is primarily associated with the administration of doses higher than recommended over a prolonged period.
Population-specific Overdose Notes	Children and adolescents may be more susceptible to systemic effects, including the risk of growth retardation.

Required Emergency Actions

Management for an overdose is defined as symptomatic and supportive, as no specific antidote is known. Urgent medical attention must be sought for any clinical features suggesting an acute adrenal crisis, which is the life-threatening outcome of severe HPA axis suppression that may be triggered by stress or illness. If evidence of prolonged high-dose use and systemic effects is observed, the official instruction is that the medicine should be gradually reduced under medical supervision.

Connection to the overall overdose profile: The regulatory documents define the overdose profile primarily through the risk of cumulative systemic corticosteroid exposure, which is measured by signs of HPA axis suppression. This classification directs emergency-seeking conditions toward the potentially life-threatening physiological consequence of chronic overuse: acute adrenal crisis.

Therapeutic Uses of Flixotide

What Flixotide Treats: Main Uses and Benefits

Proactive Control of Chronic Asthma Symptoms

The primary therapeutic role of this medicine involves long-term prophylactic anti-inflammatory management for specific chronic respiratory conditions. This treatment is commonly used across conditions characterized by periods of heightened symptoms and is considered relevant when supportive symptom management is appropriate. Flixotide is used for managing persistent asthma symptoms, playing a role in managing symptoms associated with acute or episodic changes in COPD patients, and easing symptoms of allergic rhinitis and nasal polyps.

As a controller medicine, it is used to address symptoms related to inflammatory or irritative states that create noticeable physiological strain, such as frequent wheezing, chest tightness, and severe nasal congestion. This therapeutic strategy provides support that helps ease the overall symptom burden, assists with maintaining functional stability, and contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Relief for Chronic Airway Inflammation

Flixotide is used as a controller therapy in the management of these conditions, supporting patients with conditions like asthma and COPD by addressing symptoms related to inflammatory or irritative states that create noticeable physiological strain.

Eligibility and Restrictions for Use

Who Can and Cannot Use Flixotide?

This section outlines the populations officially approved, restricted, or prohibited from using inhaled Fluticasone Propionate (Flixotide) based on regulatory prescribing information.

Populations Who Must Not Use (Contraindications)

The medicine is strictly contraindicated in two key populations:

Acute Crisis Patients: It must not be used for the primary treatment of status asthmaticus or other acute asthma episodes requiring intensive measures. Flixotide is for prophylactic (preventive) control only.
Hypersensitivity: Patients with a known allergy or hypersensitivity to Fluticasone Propionate or any other component in the specific inhaler formulation.

Official Age-Group Eligibility

Age Group	Eligibility Status (Regulatory Basis)
Adults & Adolescents (ge 12 years)	Approved for asthma maintenance therapy.
Children (ge 4 years)	Approved for asthma maintenance therapy.
Children (<4 years)	Safety and efficacy are not established for most inhaled formulations.

Conditional Use & Restrictions

Certain patient populations require a clinical assessment to determine eligibility:

Severe Hepatic Impairment: Caution is advised due to the potential for increased systemic exposure of the medicine.
Pregnancy & Breastfeeding: Use is permitted only if the potential benefit justifies the potential risk, a required clinical decision for this class of medicine.
Renal Impairment: No dose adjustment is required, implying standard eligibility.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction structure of Fluticasone Propionate based on its metabolic clearance. The medicine is primarily cleared from the body by the Cytochrome P450 3A4 (CYP3A4) pathway. Interactions occur when co-administered substances interfere with this metabolic process.

Documented Interaction Patterns

Interaction Entity	Official Outcome as Documented in Regulatory Labels
Strong CYP3A4 Inhibitors (e.g., Ritonavir, Ketoconazole)	Co-administration is not recommended due to increased systemic exposure.
Ritonavir	Documented to significantly increase Fluticasone Propionate plasma exposure.
Result of Inhibition	Risk of systemic corticosteroid effects including hypercorticism and adrenal suppression.

This pharmacokinetic interaction results in Exposure Modification, where inhibition of the CYP3A4 enzyme leads to a reduced clearance of Fluticasone Propionate. This pattern dictates that the concurrent use with potent CYP3A4 inhibitors is a major documented restriction in official prescribing information.

Population-Specific Cautions

Regulatory cautions state that patients with severe hepatic impairment may experience a slower rate of metabolism. This reduced clearance may lead to increased systemic exposure, which can contribute to the documented systemic corticosteroid effects. No specific mandatory timing separation rules are formally documented for the inhaled formulation.

Mechanism of Action

The mechanism of Flixotide (fluticasone propionate) is defined by its action as a high-affinity agonist for the intracellular Glucocorticoid Receptor (GR), primarily within inflammatory cells located in the airways. Upon binding, the drug-receptor complex translocates into the cell nucleus, where it functions as a transcription modulator.

The drug's core action is transcriptional transrepression, where the activated GR complex inhibits the activity of key pro-inflammatory transcription factors, such as NF-κB and AP-1. This molecular cascade suppresses the genes responsible for producing and releasing inflammatory mediators, including cytokines and chemokines.

This genetic modulation results in a reduction in the function, migration, and survival of inflammatory cells, such as eosinophils and T-lymphocytes, at the site of action. The overall physiological consequence of the mechanism is reduced airway tissue edema and lowered cellular responsiveness to various inflammatory stimuli.

Dosage and Administration Information

How to Use Flixotide (Fluticasone Propionate) — Official Administration Guidelines

Flixotide (Fluticasone Propionate) is administered via the oral inhalation or intranasal route, depending on the specific dosage form. The official instructions emphasize continuous, scheduled use rather than intermittent application, as maximum therapeutic benefit may not be achieved until one to two weeks of continuous use.

Administration Protocol

Feature	Official Labeled Instruction
Route of Administration	Oral Inhalation (DPI, pMDI) or Intranasal Route (Nasal Spray).
Frequency Pattern	Typically twice daily (approximately 12 hours apart) for inhalation products, or once daily for nasal spray maintenance.
Dosing Principle	The dose must be titrated (adjusted) to the lowest effective maintenance dose that controls symptoms.
Maximum Dose (Adult Inhalation)	The maximum recommended daily dosage for some adult inhalation forms is 1,000 mug twice daily.
Age-Group Rule (Pediatric Inhalation)	Recommended dosages for children aged 4 to 11 years are typically lower, such as 50 mug to 100 mug twice daily.

Procedural Requirements

Oral Inhalation: Following each dose, official instructions mandate that patients rinse the mouth with water without swallowing to comply with administration instructions. A spacer device may be recommended for use with the pressurized inhalation suspension (pMDI) to aid correct delivery.

Nasal Spray: The device requires priming (releasing test sprays into the air) before initial use or after a period of non-use. If a dose is missed, the standard procedure is to skip the missed dose and continue with the next scheduled dose; do not double the dose.

Recent Clinical Evidence

Research Evidence for Flixotide: Overview of Studies

Evidence for use in Asthma Prevention

Studies have explored the use of Flixotide (fluticasone propionate) in people diagnosed with asthma. Research has primarily focused on its role as a preventative treatment, often used daily to address the chronic nature of this condition. These trials have monitored outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level, examining whether it was associated with changes in asthma symptoms, the frequency of asthma attacks, and measures of lung function in patients needing regular treatment.

The findings describe patterns observed in the studies where changes related to the frequency and severity of asthma episodes and measurements of lung function were monitored during the study period. Research explored whether regular use was associated with changes in outcomes linked to inflammatory or irritative states in the airways.

However, the results apply only to the populations studied, and comparative evidence against all alternative treatments is not fully established. Research provides context but not a way to predict whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted. Scientists acknowledge that research is ongoing to fully contextualize the value of this medicine across all symptom patterns.

Evidence for use in Chronic Obstructive Pulmonary Disease (COPD)

Research has also examined the role of Flixotide for people with Chronic Obstructive Pulmonary Disease (COPD), which is a condition characterized by fluctuating or episodic manifestations. In this context, Flixotide was evaluated in combination with other necessary medicines for COPD (specifically, long-acting bronchodilators), as part of a multi-drug approach. Studies monitored outcomes related to systemic or functional imbalance and outcomes describing episodic or acute changes, focusing on temporary physiological imbalance to examine whether it was associated with changes in measures of breathing and quality of life.

The evidence so far indicates patterns related to monitoring outcomes capturing phases of heightened symptom activity, often referred to as exacerbations, when the medicine was used as part of a combination treatment. Research has explored short-term changes in daily functioning or activity level that were observed when participants used this medicine.

Data are still emerging regarding the best way to identify the specific subgroups of people with COPD who may have had changes in outcomes when using this medicine. Results apply only to the populations studied, and subgroup findings are uncertain, especially concerning conditions where symptoms may vary greatly in intensity. Evidence quality varies across studies, and findings help contextualize how patients reported their experience under different research scenarios.

What is Still Uncertain about Flixotide

A key part of the research landscape involves understanding what is not yet fully known about Flixotide. Evidence is limited in several key areas. For example, comparative evidence is lacking against all available alternatives across all study types. Findings were mixed concerning the optimal starting doses and how to best adjust treatment over time. Long-term effects are not fully established. Research highlights areas where more data are still emerging, and scientists are actively investigating to fill these remaining gaps.

Key Studies & References Long-term effect of inhaled corticosteroids on disease progression and mortality in chronic obstructive pulmonary disease: a systematic review and meta-analysis

How should Flixotide be stored and disposed of?

Official Storage and Disposal Requirements

Storage of Flixotide (fluticasone propionate) is governed by specific regulatory guidelines to maintain product stability and safety.

Condition	Requirement
Temperature	Store below 30, C.
Environment	Protect from direct sunlight, frost, and excessive moisture.
Prohibited Storage	Do not refrigerate or freeze the Evohaler/Inhaler. Do not expose canisters to temperatures above 50, C.
Handling	Keep the product in its original packaging and ensure the mouthpiece cover is replaced after use. The pressurized canister must not be punctured, broken, or burned.
Child Safety	The medicine must be stored out of the reach of children.
Disposal	Dispose of unused or expired product and waste material according to local requirements. Avoid discharge into drains, water courses, or the environment.